GSK’s Nucala shows consistent efficacy in COPD

GSK’s (LSE: GSK) biologic therapy Nucala (mepolizumab) has demonstrated a consistent reduction in exacerbation rates among patients with eosinophilic chronic obstructive pulmonary disease (COPD), regardless of their history of severe events.

The latest findings, presented at the 2025 American Thoracic Society International Conference and analyzed by GlobalData, underscore the growing significance of interleukin (IL)-5 inhibition and biomarker-driven strategies in COPD management.

In the Phase III MATINEE trial, Nucala reduced moderate or severe exacerbations by 25% in patients with a history of severe exacerbations and by 21% in those without such a history. The therapy also lowered the rate of exacerbations requiring emergency department visits or hospitalization-by 32% in the severe subgroup and 40% in the non-severe group-over a period of up to two years. All participants were already receiving triple inhaled therapy, reflecting current standard care.